Alpha Emitter Market By Type of Radionuclide (Lead-212, Actinium-225, Astatine-211, Radium-223, Bismuth-213, and Others), By Source (Natural Sources (Radium-226 and Uranium-238) and Artificially Produced Sources (Americium, Curium, Plutonium, and Californium)), By Application (Prostate Cancer, Bone Metastases, Pancreatic Cancer, Ovarian Cancer, Neuroendocrine Tumors, and Others), By End-user (Hospitals, Diagnostic Centers, Specialty Clinics, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: July 2024
- Report ID: 124979
- Number of Pages: 374
- Format:
-
-
-
- Telix Pharmaceuticals Ltd.
- RadioMedix Inc.
- IBA Radiopharma Solutions
- Fusion Pharmaceuticals
- Bayer AG Company Profile
- Alpha Tau Medical Ltd
- Actinium Pharmaceutical Inc.
- Orano Med
- Other Key Players
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |